| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
School of Medicine, University of New South Wales, Sydney, New South Wales, Australia;
Department of Medical Oncology, St. Vincent’s Hospital, Darlinghurst, New South Wales, Australia; and
Universitat Heidelberg, Molekulare Genetik, Heidelberg, Germany
The self-oncoprotein ErbB-2 is overexpressed in a number of malignancies. The presence of endogenous anti-ErbB-2 Ab and T cell immune responses to this protein in cancer patients has made ErbB-2 an attractive target for active immunization. However, the finding that murine anti-ErbB-2 Abs can have stimulatory, inhibitory, or no effects on cancer cell growth suggests that an inappropriately induced immune response may have an adverse effect. To ensure the induction of a beneficial Ab response, it is important to identify the epitopes recognized by these Abs. In this study we have used phage-displayed ErbB-2 gene fragment libraries and synthetic peptides to epitope-map a panel of anti-ErbB-2 mAbs. The epitopes of three mAbs, N12, N28, and L87, were successfully located to C531-A586, T216-C235, and C220-C235 of ErbB-2, respectively. It was found that while N12 inhibited tumor cell proliferation, N28 stimulated the proliferation of a subset of breast cancer cell lines overexpressing ErbB-2. The peptide region recognized by N12, (C531-A586; EP531), was used as an immunogen to selectively induce an inhibitory immune response in mice. Mice immunized with the GST fusion peptide (GST-EP531) recognized the peptide region EP531 as well as native ErbB-2. More importantly, Igs purified from mouse sera were able to inhibit up to 85% of tumor cell proliferation. In conclusion, our study provides direct evidence of the function-epitope relationship of anti-ErbB-2 Abs and also emphasizes the value of inducing a potent tumor inhibitory polyclonal Ab response by rationally selecting regions of ErbB-2 used for immunization.
This article has been cited by other articles:
|
|
 |
|
  J. T. Garrett, S. Rawale, S. D. Allen, G. Phillips, G. Forni, J. C. Morris, and P. T. P. Kaumaya Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu J. Immunol., June 1, 2007; 178(11): 7120 - 7131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Riemer, H. Kurz, M. Klinger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti-Epidermal Growth Factor Receptor Antibodies J Natl Cancer Inst, November 16, 2005; 97(22): 1663 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jiang, W. Liu, H. Qu, L. Meng, S. Song, T. Ouyang, and C. Shou A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2 J. Biol. Chem., February 11, 2005; 280(6): 4656 - 4662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wagner, C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, U. Wiedermann, H. Pehamberger, and H. Breiteneder Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro J. Immunol., January 15, 2005; 174(2): 976 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu J. Immunol., July 1, 2004; 173(1): 394 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Itoh, K. Inoue, T. Tezuka, H. Tada, Y. Hashimoto, T. Masuko, and T. Suzuki Molecular Structural and Functional Characterization of Tumor Suppressive Anti-ErbB-2 Monoclonal Antibody by Phage Display System J. Biochem., February 1, 2003; 133(2): 239 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Santin, S. Bellone, M. Gokden, M. Palmieri, D. Dunn, J. Agha, J. J. Roman, L. Hutchins, S. Pecorelli, T. O'Brien, et al. Overexpression of HER-2/Neu in Uterine Serous Papillary Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1271 - 1279. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
